Vietnam Hospitality Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report (2026-2035)

The Vietnam hospitality market reached approximately USD 6.95 Billion in 2025. The market is projected to grow at a CAGR of 12.30% between 2026 and 2035, reaching a value of around USD 22.17 Billion by 2035.

Q1 2026 Market Updates

Geopolitical Impact of Iran, US, and Israel War on the Vietnam Hospitality Market

United States: The Vietnam Hospitality Market, a key segment of the global economy, is experiencing a complex operating environment in Q1 2026 as a direct consequence of the US-Israel-Iran war. Vietnam has one of the thinnest energy buffers in Asia with oil reserves estimated at less than 20 days. Fuel prices surged approximately 50% - the highest percentage increase recorded among Southeast Asian countries. Vietnam's export-intensive economy faces rising logistics costs as ocean freight costs rise 30% and heavy freight-dependent industries including furniture, textiles, and electronics absorb higher shipping surcharges. The Vietnamese government urged citizens to work from home to conserve fuel and is weighing temporary cuts to fuel import tariffs. Vietnam's export-dependent economy faces a competitiveness risk as logistics cost inflation narrows the competitive gap with geographically closer manufacturing alternatives.

Iran: Iran's healthcare system has been severely damaged by the conflict, with the WHO identifying at least 13 health facilities as conflict-damaged. The domestic pharmaceutical and medical device sector, already severely constrained by sanctions limiting access to Western medical technology and APIs, has been further disrupted by power outages, workforce displacement, and the collapse of medical supply chain logistics. Iranian patients requiring treatment for vietnam hospitality conditions face an acute access crisis, as hospital operations are redirected toward treating conflict casualties and basic medical supplies are running low.

Israel: Israel's pharmaceutical and medical device sector is operating under emergency conditions. Israeli hospitals have moved some operations underground, medical resources are being prioritised for conflict casualties, and elective and non-emergency healthcare consumption has declined. However, Israel's biopharmaceutical research base continues to operate, with several Israeli companies involved in novel treatment development for vietnam hospitality indications. Post-conflict, Israel's healthcare system is expected to invest significantly in medical technology and pharmaceutical infrastructure restoration and capacity expansion.

Key Takeaways

Government

• Vietnamese health authorities should activate emergency pharmaceutical supply chain resilience protocols, ensuring that API and packaging material sourcing for essential vietnam hospitality treatments is not concentrated in Gulf-adjacent supply chains exposed to maritime disruption.
• Regulatory agencies should fast-track review of treatment availability and consider emergency compassionate use extensions for patients in conflict-affected regions who face interruption to their standard of care.
• Governments should monitor petrochemical-derived pharmaceutical packaging cost inflation, ensuring that price increases remain within access thresholds for patients requiring ongoing vietnam hospitality treatment.

Market

• Petrochemical-derived pharmaceutical packaging and API precursor costs are rising 15-20%, creating margin compression for vietnam hospitality manufacturers in the near term, with limited ability to pass costs through in price-regulated markets.
• The conflict's disruption to clinical trial infrastructure in Middle Eastern sites may modestly delay regulatory submissions and new treatment launches that had enrolled patients from the region, though the structural market growth trajectory remains intact.
• Healthcare system demand for vietnam hospitality treatment is fundamentally driven by disease burden and demographics rather than geopolitical events, providing strong structural insulation for the market's long-term growth trajectory.

Procurement

• Pharmaceutical procurement teams should build 90-day safety stock for essential vietnam hospitality treatment drugs and biological agents, hedging against further pharmaceutical logistics cost increases and potential supply disruptions.
• API and excipient buyers should review single-source supplier risks for Gulf-adjacent petrochemical-derived pharmaceutical inputs, establishing secondary supply arrangements with non-Gulf origin manufacturers in India, China, and Europe.
• Hospital pharmacy procurement managers should review cold-chain logistics contracts for temperature-sensitive vietnam hospitality therapeutics, ensuring that alternative air routing through non-conflict-zone hubs is available if Gulf carrier services remain suspended.